Search

Contains fulltext : 225037.pdf (Publisher’s version ) (Closed access), Although gout is the most common inflammatory arthritis, it is still frequently misdiagnosed. New data on imaging and clinical diagnosis have become available since the first EULAR recommendations for the diagnosis of gout in 2006. This prompted a systematic review and update of the 2006 recommendations. A systematic review of the literature concerning all aspects of gout diagnosis was performed. Recommendations were formulated using a Delphi consensus approach. Eight key recommendations were generated. A search for crystals in synovial fluid or tophus aspirates is recommended in every person with suspected gout, because demonstration of monosodium urate (MSU) crystals allows a definite diagnosis of gout. There was consensus that a number of suggestive clinical features support a clinical diagnosis of gout. These are monoarticular involvement of a foot or ankle joint (especially the first metatarsophalangeal joint); previous episodes of similar acute arthritis; rapid onset of severe pain and swelling; erythema; male gender and associated cardiovascular diseases and hyperuricaemia. When crystal identification is not possible, it is recommended that any atypical presentation should be investigated by imaging, in particular with ultrasound to seek features suggestive of MSU crystal deposition (double contour sign and tophi). There was consensus that a diagnosis of gout should not be based on the presence of hyperuricaemia alone. There was also a strong recommendation that all people with gout should be systematically assessed for presence of associated comorbidities and risk factors for cardiovascular disease, as well as for risk factors for chronic hyperuricaemia. Eight updated, evidence-based, expert consensus recommendations for the diagnosis of gout are proposed.

Item does not contain fulltext

Item does not contain fulltext, OBJECTIVES: To develop evidence-based recommendations for management of calcium pyrophosphate deposition (CPPD). METHODS: A multidisciplinary guideline development group of 15 experts, representing 10 European countries, generated key propositions for management of CPPD using a Delphi consensus approach. For each recommendation research evidence was searched systematically. Whenever possible, the effect size and number needed to treat for efficacy and RR or OR for side effects were calculated for individual treatment modalities. Strength of recommendation was assessed by the European League Against Rheumatism visual analogue scale. RESULTS: Nine key recommendations were generated, including topics for general management, treatment of acute attacks, prophylaxis against recurrent acute attacks and management of chronic symptoms. It was recommended that optimal treatment requires both non-pharmacological and pharmacological treatments. For acute CPP crystal arthritis, cool packs, temporary rest and joint aspiration combined with steroid injection are often sufficient. For prophylaxis or chronic inflammatory arthritis with CPPD, oral non-steroidal anti-inflammatory drugs with gastroprotective treatment and/or low-dose colchicine 0.5-1.0 mg daily may be used. Other recommendations included parenteral or oral corticosteroid for acute CPP arthritis in those unresponsive or unsuited to other measures, and low-dose corticosteroid, methotrexate or hydroxychloroquine for chronic inflammatory arthritis with CPPD. Asymptomatic CPPD requires no treatment. Strength of recommendations varies from 79% to 95%. CONCLUSION: Nine key recommendations for management of CPP crystal associated arthritis were developed using both research evidence and expert consensus. Strength of recommendations was provided to assist the application of these recommendations.

Item does not contain fulltext, OBJECTIVES: To agree terminology and to develop recommendations for the diagnosis of calcium pyrophosphate deposition (CPPD). METHODS: The European League Against Rheumatism (EULAR) CPPD Task Force, comprising 15 experts from 10 countries, agreed the terms and recommendations for diagnosis of CPPD using a Delphi consensus approach. Evidence was systematically reviewed and presented in terms of sensitivity, specificity and positive likelihood ratio (LR) to support diagnosis; ORs were used for association. Strength of recommendation (SOR) was assessed by the EULAR visual analogue scale. RESULTS: It was agreed that 'CPPD' should be the umbrella term that includes acute calcium pyrophosphate (CPP) crystal arthritis, osteoarthritis (OA) with CPPD and chronic CPP crystal inflammatory arthritis. Chondrocalcinosis (CC) defines cartilage calcification, most commonly due to CPPD and detected by imaging or histological examination. A total of 11 key recommendations were generated on the topics of clinical features, synovial fluid (SF) examination, imaging, comorbidities and risk factors. Definitive diagnosis of CPPD relies on identification of SF CPP crystals. Rapid onset inflammatory symptoms and signs are suggestive but not definitive for acute CPP crystal arthritis. Radiographic CC is not highly sensitive or specific, whereas ultrasonography appears more useful (LR=24.2, 95% CI 3.51 to 168.01) for peripheral joints. Recognised risk factors for CPPD include ageing, OA and metabolic conditions such as primary hyperparathyroidism, haemochromatosis and hypomagnesaemia; familial forms are rare. SORs varied from 53 to 99 (maximum 100). CONCLUSION: New terms for CPPD were agreed and 11 key recommendations for diagnosis of CPPD were developed using research evidence and expert consensus.

Measuring precisely the faint polarization of the Far-Infrared and sub-millimetre sky is the next observational challenge of modern astronomy. In particular, detection the B-mode polarization from the Cosmic Microwave Background (CMB) shall reveal the inflationary periods in the very early universe. Such measurements will require very high sensitivity and very low instrumental systematic effects. As for measurements of the CMB intensity, sensitive measurements of the CMB polarization will be made difficult by the presence of foreground emission from our own Milky Way, which is orders of magnitude higher than the faint polarized cosmological signal. Such foreground emission will have to be understood very accurately and removed from cosmological measurements. This polarized emission is also interesting in itself, since it brings information relevant to star formation processes, about the orientation of the magnetic field in our Galaxy through the alignment of dust grains. I will first summarize our current knowledge in this field. I will then describe the PILOT balloon-borne experiment project, which is dedicated to measuring precisely the polarization of faint diffuse dust emission in the Far-Infrared in our Galaxy.

Measuring precisely the faint polarization of the Far-Infrared and sub-millimetre sky is the next observational challenge of modern astronomy. In particular, detection the B-mode polarization from the Cosmic Microwave Background (CMB) shall reveal the inflationary periods in the very early universe. Such measurements will require very high sensitivity and very low instrumental systematic effects. As for measurements of the CMB intensity, sensitive measurements of the CMB polarization will be made difficult by the presence of foreground emission from our own Milky Way, which is orders of magnitude higher than the faint polarized cosmological signal. Such foreground emission will have to be understood very accurately and removed from cosmological measurements. This polarized emission is also interesting in itself, since it brings information relevant to star formation processes, about the orientation of the magnetic field in our Galaxy through the alignment of dust grains. I will first summarize our current knowledge in this field. I will then describe the PILOT balloon-borne experiment project, which is dedicated to measuring precisely the polarization of faint diffuse dust emission in the Far-Infrared in our Galaxy.